Neoadjuvant Therapy of Anlotinib Combined With Toripalimab and Chemotherapy for Resectable Esophageal Carcinoma

NCT05996484 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Carcinoma
Neoadjuvant Therapy

Interventions

DRUG: Toripalimab
DRUG: Anlotinib hydrochloride
DRUG: Albumin paclitaxel
DRUG: Cisplatin

Sponsor

Nanfang Hospital, Southern Medical University